Natco Pharma has a Cash Ratio of 1.90. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Natco Pharma's Cash Ratio or its related term are showing as below:
NSE:NATCOPHARM'
s Cash Ratio Range Over the Past 10 Years
Min: 0.03 Med: 1.38 Max: 1.9
Current: 1.9
During the past 13 years, Natco Pharma's highest Cash Ratio was 1.90. The lowest was 0.03. And the median was 1.38.
NSE:NATCOPHARM's Cash Ratio is ranked better than 78.12% of 1033
companies
in the Drug Manufacturers industry
Industry Median: 0.57
vs NSE:NATCOPHARM: 1.90
Natco Pharma Cash Ratio Historical Data
The historical data trend for Natco Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Natco Pharma's Cash Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natco Pharma's Cash Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Natco Pharma's Cash Ratio falls into.
Natco Pharma Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Natco Pharma's Cash Ratio for the fiscal year that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natco Pharma (NSE:NATCOPHARM) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Natco Pharma Cash Ratio Related Terms
Thank you for viewing the detailed overview of Natco Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Natco Pharma (NSE:NATCOPHARM) Business Description
Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:NATCOPHARM has been successfully added to your 